| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniosynostoses | 10 | 2021 | 132 | 1.000 |
Why?
|
| Moyamoya Disease | 4 | 2018 | 38 | 0.940 |
Why?
|
| Medulloblastoma | 9 | 2020 | 340 | 0.780 |
Why?
|
| Brain Neoplasms | 18 | 2019 | 1243 | 0.780 |
Why?
|
| Dura Mater | 2 | 2018 | 26 | 0.750 |
Why?
|
| Cerebellar Neoplasms | 8 | 2020 | 285 | 0.670 |
Why?
|
| Cerebral Revascularization | 3 | 2018 | 21 | 0.660 |
Why?
|
| Glioma | 8 | 2021 | 500 | 0.620 |
Why?
|
| Spina Bifida Occulta | 2 | 2014 | 3 | 0.580 |
Why?
|
| Hydrocephalus | 10 | 2011 | 244 | 0.540 |
Why?
|
| Cranial Sutures | 4 | 2021 | 32 | 0.510 |
Why?
|
| Dermoid Cyst | 1 | 2014 | 34 | 0.450 |
Why?
|
| Skull | 5 | 2021 | 142 | 0.450 |
Why?
|
| Proton Therapy | 4 | 2019 | 123 | 0.410 |
Why?
|
| Cerebrospinal Fluid Shunts | 6 | 1998 | 79 | 0.390 |
Why?
|
| Child, Preschool | 44 | 2019 | 14043 | 0.380 |
Why?
|
| Infant | 37 | 2021 | 12473 | 0.370 |
Why?
|
| Brain | 5 | 2021 | 3004 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2021 | 3575 | 0.360 |
Why?
|
| Ependymoma | 4 | 2017 | 134 | 0.350 |
Why?
|
| Spinal Fusion | 4 | 2021 | 114 | 0.350 |
Why?
|
| Child | 52 | 2021 | 24439 | 0.330 |
Why?
|
| Photons | 2 | 2019 | 48 | 0.320 |
Why?
|
| Macaca mulatta | 16 | 2011 | 493 | 0.290 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2017 | 70 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2020 | 2089 | 0.280 |
Why?
|
| Male | 68 | 2021 | 61053 | 0.270 |
Why?
|
| Hematoma | 2 | 2020 | 92 | 0.270 |
Why?
|
| Neurosurgical Procedures | 3 | 2017 | 307 | 0.270 |
Why?
|
| Calcinosis | 2 | 2020 | 175 | 0.260 |
Why?
|
| Syringomyelia | 2 | 2021 | 17 | 0.250 |
Why?
|
| Pituitary Neoplasms | 2 | 2014 | 84 | 0.250 |
Why?
|
| Arnold-Chiari Malformation | 2 | 2021 | 51 | 0.240 |
Why?
|
| Humans | 83 | 2021 | 124482 | 0.240 |
Why?
|
| Radiation Injuries | 4 | 2019 | 143 | 0.240 |
Why?
|
| Adolescent | 30 | 2019 | 19301 | 0.240 |
Why?
|
| Female | 54 | 2021 | 66319 | 0.220 |
Why?
|
| Treatment Outcome | 19 | 2021 | 12315 | 0.220 |
Why?
|
| Meningomyelocele | 3 | 2011 | 237 | 0.220 |
Why?
|
| Ventriculoperitoneal Shunt | 3 | 2010 | 49 | 0.210 |
Why?
|
| Retrospective Studies | 24 | 2021 | 16270 | 0.210 |
Why?
|
| Cerebral Angiography | 3 | 2018 | 102 | 0.200 |
Why?
|
| Protons | 2 | 2020 | 91 | 0.190 |
Why?
|
| Spine | 3 | 2011 | 143 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 2 | 2018 | 252 | 0.190 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 225 | 0.190 |
Why?
|
| Craniospinal Irradiation | 2 | 2019 | 58 | 0.190 |
Why?
|
| Esthetics, Dental | 1 | 2021 | 16 | 0.180 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2009 | 71 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 104 | 0.180 |
Why?
|
| Astrocytoma | 4 | 2013 | 103 | 0.170 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 93 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 300 | 0.170 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 161 | 0.170 |
Why?
|
| Reoperation | 8 | 2012 | 831 | 0.170 |
Why?
|
| Antigens, CD | 2 | 2014 | 422 | 0.170 |
Why?
|
| Glycoproteins | 2 | 2014 | 369 | 0.160 |
Why?
|
| Osteotomy | 2 | 2019 | 39 | 0.160 |
Why?
|
| Intelligence | 1 | 2019 | 98 | 0.160 |
Why?
|
| Vision Disorders | 3 | 2013 | 212 | 0.160 |
Why?
|
| Catheters, Indwelling | 3 | 2004 | 156 | 0.150 |
Why?
|
| Area Under Curve | 11 | 2010 | 316 | 0.150 |
Why?
|
| Peptides | 2 | 2014 | 794 | 0.150 |
Why?
|
| Osteopontin | 1 | 2018 | 49 | 0.150 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 1661 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2018 | 93 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2006 | 181 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2019 | 368 | 0.140 |
Why?
|
| Cranial Irradiation | 2 | 2008 | 69 | 0.140 |
Why?
|
| Head Protective Devices | 2 | 2019 | 24 | 0.140 |
Why?
|
| Teaching | 1 | 1998 | 189 | 0.130 |
Why?
|
| Adenoma | 1 | 1998 | 135 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 168 | 0.130 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2016 | 6 | 0.130 |
Why?
|
| Arabinonucleosides | 2 | 2006 | 32 | 0.130 |
Why?
|
| Cysts | 2 | 1994 | 101 | 0.130 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 1460 | 0.130 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 36 | 0.120 |
Why?
|
| Cerebral Ventricles | 2 | 1994 | 81 | 0.120 |
Why?
|
| Postoperative Complications | 7 | 2011 | 3066 | 0.120 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 1995 | 14 | 0.120 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 29 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 579 | 0.120 |
Why?
|
| Craniopharyngioma | 1 | 2014 | 33 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2019 | 295 | 0.120 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 1995 | 41 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2014 | 886 | 0.120 |
Why?
|
| Occipital Bone | 1 | 2014 | 21 | 0.120 |
Why?
|
| Papilledema | 2 | 1994 | 79 | 0.120 |
Why?
|
| Education, Medical | 1 | 1998 | 287 | 0.110 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 5125 | 0.110 |
Why?
|
| Silicone Elastomers | 1 | 1994 | 35 | 0.110 |
Why?
|
| Punctures | 1 | 1994 | 55 | 0.110 |
Why?
|
| Brain Diseases | 2 | 1994 | 300 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 89 | 0.110 |
Why?
|
| Lipoma | 1 | 1993 | 24 | 0.110 |
Why?
|
| Spinal Cord Injuries | 3 | 2008 | 311 | 0.110 |
Why?
|
| Cyclophosphamide | 3 | 2008 | 421 | 0.110 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2011 | 53 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 82 | 0.110 |
Why?
|
| Nitric Oxide | 1 | 2016 | 445 | 0.100 |
Why?
|
| Indoles | 2 | 2004 | 181 | 0.100 |
Why?
|
| Animals | 24 | 2021 | 34157 | 0.100 |
Why?
|
| Skull Neoplasms | 1 | 1992 | 14 | 0.100 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 112 | 0.100 |
Why?
|
| Aneurysm, Ruptured | 1 | 2012 | 36 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 701 | 0.100 |
Why?
|
| Young Adult | 5 | 2018 | 8970 | 0.100 |
Why?
|
| Vincristine | 2 | 2010 | 195 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 189 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 333 | 0.100 |
Why?
|
| Sympathectomy | 1 | 2011 | 7 | 0.100 |
Why?
|
| Infusions, Intravenous | 8 | 2006 | 549 | 0.100 |
Why?
|
| Amenorrhea | 1 | 2011 | 19 | 0.100 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 1892 | 0.100 |
Why?
|
| Thalidomide | 1 | 2011 | 36 | 0.090 |
Why?
|
| Intracranial Aneurysm | 1 | 2012 | 93 | 0.090 |
Why?
|
| Cauda Equina | 1 | 2011 | 9 | 0.090 |
Why?
|
| Ventriculostomy | 1 | 2011 | 36 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 860 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2011 | 41 | 0.090 |
Why?
|
| Mutation | 2 | 2016 | 5805 | 0.090 |
Why?
|
| Kyphosis | 1 | 2011 | 22 | 0.090 |
Why?
|
| Radiotherapy Dosage | 3 | 2019 | 187 | 0.090 |
Why?
|
| Bone Screws | 1 | 2011 | 51 | 0.090 |
Why?
|
| Radiography | 5 | 2015 | 827 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 212 | 0.090 |
Why?
|
| Spinal Cord | 3 | 1991 | 303 | 0.090 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 33 | 0.090 |
Why?
|
| Gene Amplification | 2 | 2009 | 228 | 0.090 |
Why?
|
| Face | 1 | 1992 | 180 | 0.090 |
Why?
|
| Ear, External | 1 | 2011 | 22 | 0.090 |
Why?
|
| Craniotomy | 4 | 2020 | 108 | 0.090 |
Why?
|
| Long QT Syndrome | 1 | 2011 | 85 | 0.090 |
Why?
|
| Vein of Galen Malformations | 1 | 2010 | 7 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 127 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 618 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2011 | 342 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2008 | 52 | 0.090 |
Why?
|
| Subarachnoid Space | 1 | 2010 | 25 | 0.090 |
Why?
|
| Respiratory Tract Fistula | 1 | 2010 | 15 | 0.090 |
Why?
|
| Plagiocephaly, Nonsynostotic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Ear | 1 | 2010 | 25 | 0.090 |
Why?
|
| Pleural Diseases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Eosinophilic Granuloma | 1 | 1989 | 3 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 124 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 225 | 0.080 |
Why?
|
| Cytarabine | 1 | 2010 | 98 | 0.080 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2010 | 127 | 0.080 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 111 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 2007 | 63 | 0.080 |
Why?
|
| Spinal Diseases | 1 | 1989 | 46 | 0.080 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2009 | 23 | 0.080 |
Why?
|
| Thoracotomy | 1 | 2010 | 109 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 2010 | 105 | 0.080 |
Why?
|
| Osteoma, Osteoid | 1 | 1989 | 4 | 0.080 |
Why?
|
| Axis, Cervical Vertebra | 1 | 1989 | 3 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 237 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2008 | 1196 | 0.080 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 24 | 0.080 |
Why?
|
| Atlanto-Axial Joint | 1 | 1989 | 21 | 0.080 |
Why?
|
| Fasciitis | 1 | 2008 | 20 | 0.080 |
Why?
|
| Hematoma, Epidural, Spinal | 1 | 2008 | 7 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2008 | 117 | 0.080 |
Why?
|
| Lymphangioma | 1 | 2008 | 22 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2009 | 133 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 5 | 2009 | 143 | 0.080 |
Why?
|
| Supratentorial Neoplasms | 1 | 2008 | 37 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2008 | 40 | 0.070 |
Why?
|
| Survival Rate | 4 | 2019 | 2028 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 459 | 0.070 |
Why?
|
| Physical Therapy Modalities | 1 | 2008 | 51 | 0.070 |
Why?
|
| Ophthalmic Artery | 1 | 2007 | 24 | 0.070 |
Why?
|
| Neural Tube Defects | 1 | 2011 | 351 | 0.070 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2007 | 20 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 197 | 0.070 |
Why?
|
| Ganglioglioma | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1289 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 1990 | 265 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1697 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 372 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2007 | 47 | 0.070 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2007 | 45 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 1992 | 519 | 0.070 |
Why?
|
| Rhabdoid Tumor | 2 | 1997 | 50 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2009 | 441 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1392 | 0.070 |
Why?
|
| Cerebellum | 2 | 2009 | 416 | 0.070 |
Why?
|
| Oligodendroglia | 1 | 2007 | 84 | 0.070 |
Why?
|
| Folic Acid Antagonists | 1 | 2006 | 16 | 0.070 |
Why?
|
| Neuroendoscopy | 2 | 2020 | 26 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 124 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2016 | 4535 | 0.070 |
Why?
|
| Glutamates | 1 | 2006 | 67 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 60 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 1288 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 530 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2007 | 198 | 0.060 |
Why?
|
| Walking | 1 | 2008 | 214 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 266 | 0.060 |
Why?
|
| Axonal Transport | 1 | 1984 | 22 | 0.060 |
Why?
|
| Biopsy | 3 | 2018 | 1236 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2004 | 10 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 1989 | 429 | 0.060 |
Why?
|
| Carbazoles | 1 | 2004 | 33 | 0.060 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2004 | 16 | 0.060 |
Why?
|
| Proline | 1 | 1984 | 77 | 0.060 |
Why?
|
| Somatosensory Cortex | 1 | 1984 | 53 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 52 | 0.060 |
Why?
|
| Motor Cortex | 1 | 1984 | 76 | 0.060 |
Why?
|
| Camptothecin | 1 | 2004 | 76 | 0.050 |
Why?
|
| Equipment Failure | 2 | 1998 | 123 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 128 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 327 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 1112 | 0.050 |
Why?
|
| Half-Life | 3 | 2010 | 156 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2010 | 1242 | 0.050 |
Why?
|
| Spinal Cord Compression | 1 | 1982 | 31 | 0.050 |
Why?
|
| Fatal Outcome | 3 | 2010 | 356 | 0.050 |
Why?
|
| AC133 Antigen | 2 | 2014 | 35 | 0.050 |
Why?
|
| Pyrroles | 1 | 2003 | 179 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 358 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1236 | 0.050 |
Why?
|
| Phenylacetates | 1 | 2001 | 23 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2008 | 2613 | 0.050 |
Why?
|
| Sea Urchins | 1 | 2021 | 7 | 0.050 |
Why?
|
| Adult | 11 | 2018 | 29395 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2001 | 76 | 0.040 |
Why?
|
| Phenylbutyrates | 1 | 2001 | 58 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 578 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2000 | 76 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2000 | 24 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 1987 | 1088 | 0.040 |
Why?
|
| Intelligence Tests | 1 | 2019 | 57 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 1273 | 0.040 |
Why?
|
| Scoliosis | 2 | 2011 | 135 | 0.040 |
Why?
|
| Thoracic Vertebrae | 2 | 2011 | 69 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 764 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 4751 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2018 | 8180 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2000 | 144 | 0.040 |
Why?
|
| Epilepsy | 1 | 1987 | 872 | 0.040 |
Why?
|
| Ganciclovir | 1 | 1999 | 103 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 1979 | 145 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1020 | 0.040 |
Why?
|
| Age Factors | 3 | 2015 | 2810 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 2040 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2010 | 570 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2010 | 678 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 471 | 0.040 |
Why?
|
| Cervical Vertebrae | 2 | 2008 | 113 | 0.040 |
Why?
|
| Anatomy, Artistic | 1 | 1997 | 5 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2007 | 24 | 0.040 |
Why?
|
| Meningeal Arteries | 1 | 1997 | 12 | 0.030 |
Why?
|
| Medical Illustration | 1 | 1997 | 18 | 0.030 |
Why?
|
| Regeneration | 1 | 1979 | 203 | 0.030 |
Why?
|
| Prognosis | 3 | 2014 | 4572 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 142 | 0.030 |
Why?
|
| Pyramidal Tracts | 2 | 2011 | 36 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2008 | 255 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2016 | 9 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 316 | 0.030 |
Why?
|
| Risk Factors | 4 | 2015 | 10181 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 1997 | 149 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 4355 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 51 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1322 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 6082 | 0.030 |
Why?
|
| Tegmentum Mesencephali | 1 | 1995 | 3 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.030 |
Why?
|
| Choroid Plexus | 1 | 1995 | 24 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 1997 | 204 | 0.030 |
Why?
|
| Cerebral Ventriculography | 1 | 1994 | 2 | 0.030 |
Why?
|
| Mice | 4 | 2014 | 17736 | 0.030 |
Why?
|
| Body Water | 1 | 1995 | 90 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.030 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 37 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2006 | 331 | 0.030 |
Why?
|
| Learning | 1 | 1998 | 363 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 63 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2007 | 1898 | 0.030 |
Why?
|
| Intraoperative Period | 3 | 2007 | 75 | 0.030 |
Why?
|
| Ocular Hypertension | 1 | 1994 | 26 | 0.030 |
Why?
|
| Brain Stem | 1 | 2015 | 116 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2014 | 30 | 0.030 |
Why?
|
| Schwann Cells | 1 | 1994 | 59 | 0.030 |
Why?
|
| Optic Atrophy | 1 | 1994 | 47 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 54 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 260 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 775 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 133 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 151 | 0.030 |
Why?
|
| Headache | 1 | 1994 | 108 | 0.030 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1993 | 10 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 2 | 2004 | 95 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 543 | 0.030 |
Why?
|
| Visual Fields | 1 | 1994 | 133 | 0.030 |
Why?
|
| Frontal Bone | 1 | 1993 | 16 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1994 | 70 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1999 | 746 | 0.030 |
Why?
|
| Peritoneum | 2 | 1991 | 36 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 136 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2007 | 1490 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 710 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 39 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1993 | 194 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1017 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 59 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 669 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 191 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 510 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 355 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 1993 | 182 | 0.020 |
Why?
|
| Stellate Ganglion | 1 | 2011 | 9 | 0.020 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2012 | 74 | 0.020 |
Why?
|
| Ganglia, Sympathetic | 1 | 2011 | 23 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1250 | 0.020 |
Why?
|
| Atenolol | 1 | 2011 | 43 | 0.020 |
Why?
|
| Equipment Design | 1 | 1994 | 599 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 427 | 0.020 |
Why?
|
| Third Ventricle | 1 | 2011 | 29 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1419 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 1991 | 41 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1687 | 0.020 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2011 | 7 | 0.020 |
Why?
|
| Syncope | 1 | 2011 | 52 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1994 | 488 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 3097 | 0.020 |
Why?
|
| Neurons | 1 | 2001 | 1966 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1017 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1686 | 0.020 |
Why?
|
| Fentanyl | 1 | 2011 | 48 | 0.020 |
Why?
|
| Thiourea | 1 | 2010 | 9 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 339 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Hemiplegia | 1 | 2010 | 42 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2010 | 84 | 0.020 |
Why?
|
| Ganglioneuroma | 1 | 2010 | 17 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 11 | 0.020 |
Why?
|
| Logistic Models | 2 | 2011 | 1807 | 0.020 |
Why?
|
| Safety | 1 | 2011 | 218 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 118 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1994 | 1190 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2011 | 324 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2010 | 36 | 0.020 |
Why?
|
| Life Tables | 1 | 1990 | 30 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2010 | 209 | 0.020 |
Why?
|
| Visual Acuity | 1 | 1994 | 824 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 241 | 0.020 |
Why?
|
| Bone Transplantation | 1 | 1989 | 49 | 0.020 |
Why?
|
| Thorax | 1 | 1989 | 72 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 195 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2010 | 101 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 30 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1993 | 429 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 376 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 281 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 60 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2011 | 192 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 2989 | 0.020 |
Why?
|
| Rotation | 1 | 1989 | 51 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2013 | 553 | 0.020 |
Why?
|
| Neck | 1 | 1989 | 137 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 65 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 49 | 0.020 |
Why?
|
| Immobilization | 1 | 1988 | 24 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 238 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 290 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 235 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2823 | 0.020 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2007 | 1 | 0.020 |
Why?
|
| Biological Dressings | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 73 | 0.020 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Anaplasia | 1 | 2007 | 6 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 254 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2007 | 69 | 0.020 |
Why?
|
| Aging | 1 | 1994 | 1187 | 0.020 |
Why?
|
| Exophthalmos | 1 | 2007 | 37 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 113 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 374 | 0.020 |
Why?
|
| Middle Aged | 6 | 2016 | 26511 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2868 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 236 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2008 | 225 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 301 | 0.020 |
Why?
|
| Wounds, Gunshot | 1 | 2008 | 139 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2006 | 9 | 0.020 |
Why?
|
| Prodrugs | 1 | 2006 | 59 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 98 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 1988 | 187 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 291 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 298 | 0.020 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 41 | 0.020 |
Why?
|
| Rats | 2 | 1984 | 3685 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2006 | 284 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 1459 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 382 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 233 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 785 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3588 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 677 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 616 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1400 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 1984 | 81 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 660 | 0.010 |
Why?
|
| Hypophysectomy | 1 | 1983 | 20 | 0.010 |
Why?
|
| Sphenoid Sinus | 1 | 1983 | 12 | 0.010 |
Why?
|
| Paranasal Sinus Diseases | 1 | 1983 | 20 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 524 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2004 | 145 | 0.010 |
Why?
|
| Carotid Artery Injuries | 1 | 1983 | 40 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2007 | 539 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2006 | 334 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 332 | 0.010 |
Why?
|
| United States | 1 | 1998 | 10821 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1984 | 267 | 0.010 |
Why?
|
| Myelography | 1 | 1982 | 9 | 0.010 |
Why?
|
| Orbit | 2 | 1993 | 102 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 211 | 0.010 |
Why?
|
| Stroke | 1 | 2010 | 977 | 0.010 |
Why?
|
| Laminectomy | 1 | 1982 | 27 | 0.010 |
Why?
|
| Kinetics | 1 | 1984 | 1321 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 185 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1749 | 0.010 |
Why?
|
| Paraplegia | 1 | 1982 | 94 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1616 | 0.010 |
Why?
|
| Carotid Artery Diseases | 1 | 1983 | 146 | 0.010 |
Why?
|
| Muscle Spasticity | 1 | 1982 | 73 | 0.010 |
Why?
|
| Electromyography | 1 | 1982 | 165 | 0.010 |
Why?
|
| Synaptophysin | 1 | 2001 | 17 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 35 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 2127 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 1113 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2001 | 107 | 0.010 |
Why?
|
| Pharmaceutic Aids | 1 | 2000 | 3 | 0.010 |
Why?
|
| Povidone | 1 | 2000 | 5 | 0.010 |
Why?
|
| Cefazolin | 1 | 2000 | 20 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2001 | 187 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 2551 | 0.010 |
Why?
|
| Isoflurane | 1 | 2000 | 42 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 45 | 0.010 |
Why?
|
| Recurrence | 2 | 1995 | 1423 | 0.010 |
Why?
|
| Penicillins | 1 | 2000 | 154 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2303 | 0.010 |
Why?
|
| Cephalosporins | 1 | 2000 | 137 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1931 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1983 | 464 | 0.010 |
Why?
|
| Afferent Pathways | 1 | 1979 | 21 | 0.010 |
Why?
|
| Buprenorphine | 1 | 2000 | 95 | 0.010 |
Why?
|
| Benzamides | 1 | 2000 | 106 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4258 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 6285 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 197 | 0.010 |
Why?
|
| Ultrasonography | 2 | 1991 | 929 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 409 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1017 | 0.010 |
Why?
|
| Diffusion | 1 | 1995 | 59 | 0.010 |
Why?
|
| Anisotropy | 1 | 1995 | 122 | 0.010 |
Why?
|
| Craniofacial Dysostosis | 1 | 1995 | 19 | 0.010 |
Why?
|
| Esthetics | 1 | 1994 | 37 | 0.010 |
Why?
|
| Malocclusion, Angle Class III | 1 | 1993 | 6 | 0.010 |
Why?
|
| Forehead | 1 | 1993 | 13 | 0.010 |
Why?
|
| Facial Bones | 1 | 1993 | 28 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 780 | 0.010 |
Why?
|
| Photography | 1 | 1993 | 92 | 0.010 |
Why?
|
| Cell Survival | 1 | 1994 | 804 | 0.010 |
Why?
|
| Cranial Fossa, Posterior | 1 | 1991 | 14 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 1277 | 0.010 |
Why?
|
| Aged | 3 | 1995 | 19549 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1995 | 547 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1994 | 3052 | 0.000 |
Why?
|
| Rupture | 1 | 1983 | 32 | 0.000 |
Why?
|
| Ligation | 1 | 1983 | 135 | 0.000 |
Why?
|
| Carotid Artery, Internal | 1 | 1983 | 67 | 0.000 |
Why?
|